The Niche Episode 021 – Pfizer, mRNA Vaccine Function, and Novartis + Mesoblast
Pfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million
Story References
https://www.biospace.com/article/pfizer-and-biontech-to-submit-covid-19-vaccine-to-fda-for-emergency-use-today/
https://www.biospace.com/article/releases/stoke-therapeutics-announces-pricing-of-97-5-million-public-offering/
https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy
Sponsors
https://www.thescopemethod.com
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.